Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Silo Pharma Inc (NQ: SILO )

3.500 -0.050 (-1.41%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 12,743
Open 3.360
Bid (Size) 3.390 (5)
Ask (Size) 3.500 (7)
Prev. Close 3.550
Today's Range 3.350 - 3.510
52wk Range 3.000 - 7.260
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) CEO Discusses Advancement of Pipeline, Positioning in Shareholder Letter
Via Investor Brand Network
Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets Combining Traditional Therapeutics with Psychedelic Medicine
From Silo Pharma, Inc.
Via Globe NewsWire

Performance

YTD
-31.37%
-31.37%
1 Month
-9.09%
-9.09%
3 Month
-31.37%
-31.37%
6 Month
-31.37%
-31.37%
1 Year
-31.37%
-31.37%

More News

Read More
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advancing Research of SPU-21 in Human Synovial Tissue
Via Investor Brand Network
Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue
From Silo Pharma, Inc.
Via Globe NewsWire
7 Millionaire-Maker Stocks You Will Regret Not Buying This Year
Via InvestorPlace
Novel Psychedelic Compound For The Treatment Of Fibromyalgia Begins Dosing In Safety Trial
Via Benzinga
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Milestone in IND-Enabling Study of Time-Released Ketamine Formulation
Via Investor Brand Network
Silo Pharma Achieves New Milestone for SP-26 Therapeutic -Initiates IND Enabling Study of Topical Ketamine Formulation
From Silo Pharma, Inc.
Via Globe NewsWire
New Psychedelic Journal to Focus on Publishing Psychedelic Research
Via Investor Brand Network
Silo Pharma Inc. (NASDAQ: SILO) Extends Columbia University Agreement to Continue Research for Therapeutics to Treat Alzheimer’s Disease
Via Investor Brand Network
PsychedelicNewsBreaks – Silo Pharma Inc. (SILO) Confident in Preclinical Work on Its Novel Ketamine Formulation
Via Investor Brand Network
Microscopy Provides Insights on Psychedelics Action Inside Neuropathways
Via Investor Brand Network
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Present at Largest Gathering in Psychedelic Medicine Sector
Via Investor Brand Network
Silo Pharma to Discuss Mainstream Pharma and Psychedelics at Wonderland Miami Conference
From Silo Pharma, Inc.
Via Globe NewsWire
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Distinctive with Ground-Breaking Research, Commitment to Developing Innovative Solutions
Via Investor Brand Network
What You Should Know About Colorado’s Psychedelics Ballot Measure
Via Investor Brand Network
Silo Pharma Inc.’s (NASDAQ: SILO) Novel Ketamine Formulation Undergoing Safety Evaluation, Pursuing Regulatory Pathway
Via Investor Brand Network
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Data Supporting SPC-14’s Therapeutic Potential for Alzheimer’s
Via Investor Brand Network
Exposures Product Safety
What Is Going on With Silo Pharma (SILO) Stock Today?
Via InvestorPlace
Alzheimer’s Pipeline of New Treatments Race to Improve Quality of Life for Patients
Via FinancialNewsMedia
Silo Pharma Announces Data Supporting Therapeutic Potential of SPC-14 for Alzheimer’s Disease in Pre-Clinical Study
Via FinancialNewsMedia
Silo Pharma Posts Encouraging Preclinical Data For Alzheimer's Candidate
Via Benzinga
Silo Pharma Announces Data Supporting Therapeutic Potential of SPC-14 for Alzheimer’s Disease in Pre-Clinical Study
From Silo Pharma, Inc.
Via Globe NewsWire
Psychedelics For Alzheimer's And Stress-Induced Disorders Under Study At Columbia University
Via Benzinga
Florida Dispensary Uncovers Legal Loophole, Starts Selling Shrooms
Via Investor Brand Network
Topics Law Enforcement
Exposures Legal
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.